share_log

Mangoceuticals | SC 13D/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Jacob D. Cohen(34.2%),The Tiger Cub Trust(30.3%)

Mangoceuticals | SC 13D/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Jacob D. Cohen(34.2%),The Tiger Cub Trust(30.3%)

Mangoceuticals | SC 13D/A:超過5%持股股東披露文件(修正)-Jacob D. Cohen(34.2%),The Tiger Cub Trust(30.3%)
美股SEC公告 ·  08/27 19:50

Moomoo AI 已提取核心訊息

On August 27, 2024, Mangoceuticals, Inc. experienced a significant change in its shareholder structure, as detailed in the latest Schedule 13D/A filing with the United States Securities and Exchange Commission. Jacob D. Cohen, a major shareholder, reported a transfer of 800,000 shares of common stock to The Tiger Cub Trust, an entity he controls, without any consideration. This amendment, identified as Amendment No. 3, supplements previous filings made on May 3, 2023, January 2, 2024, and June 5, 2024. Following this gifting of shares, Jacob D. Cohen and The Tiger Cub Trust collectively hold an aggregate of 10,825,000 shares, representing 34.2% of the company's issued common stock. The Tiger Cub Trust alone holds 9,075,000 shares, accounting for 30.3% of the common stock. The filing also notes that Cohen has sole voting and dispositive power over 1,750,000 shares, which includes shares issuable upon the exercise of vested options. The total number of common shares outstanding as confirmed by Mangoceuticals' transfer agent is 29,905,803.
On August 27, 2024, Mangoceuticals, Inc. experienced a significant change in its shareholder structure, as detailed in the latest Schedule 13D/A filing with the United States Securities and Exchange Commission. Jacob D. Cohen, a major shareholder, reported a transfer of 800,000 shares of common stock to The Tiger Cub Trust, an entity he controls, without any consideration. This amendment, identified as Amendment No. 3, supplements previous filings made on May 3, 2023, January 2, 2024, and June 5, 2024. Following this gifting of shares, Jacob D. Cohen and The Tiger Cub Trust collectively hold an aggregate of 10,825,000 shares, representing 34.2% of the company's issued common stock. The Tiger Cub Trust alone holds 9,075,000 shares, accounting for 30.3% of the common stock. The filing also notes that Cohen has sole voting and dispositive power over 1,750,000 shares, which includes shares issuable upon the exercise of vested options. The total number of common shares outstanding as confirmed by Mangoceuticals' transfer agent is 29,905,803.
2024年8月27日,Mangoceuticals公司的股東結構發生了重大變化,詳細情況在最新提交給美國證券交易委員會的13D/A表中說明。主要股東Jacob D. Cohen向其控制的The Tiger Cub Trust轉讓了80萬股普通股,沒有任何對價。此修正案編號爲第3號,補充了2023年5月3日、2024年1月2日和2024年6月5日的先前申報。在這次贈予股份之後,Jacob D. Cohen和The Tiger Cub Trust共持有1,082.5萬股,佔公司發行普通股的34.2%。The Tiger Cub Trust獨自持有907.5萬股,佔普通股的30.3%。申報還指出,Cohen對175萬股擁有唯一的表決權和實際決策權,其中包括可行權的股份。由Mangoceuticals的過戶代理機構確認的普通股總數爲2,990.5萬股。
2024年8月27日,Mangoceuticals公司的股東結構發生了重大變化,詳細情況在最新提交給美國證券交易委員會的13D/A表中說明。主要股東Jacob D. Cohen向其控制的The Tiger Cub Trust轉讓了80萬股普通股,沒有任何對價。此修正案編號爲第3號,補充了2023年5月3日、2024年1月2日和2024年6月5日的先前申報。在這次贈予股份之後,Jacob D. Cohen和The Tiger Cub Trust共持有1,082.5萬股,佔公司發行普通股的34.2%。The Tiger Cub Trust獨自持有907.5萬股,佔普通股的30.3%。申報還指出,Cohen對175萬股擁有唯一的表決權和實際決策權,其中包括可行權的股份。由Mangoceuticals的過戶代理機構確認的普通股總數爲2,990.5萬股。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息